Anticancer (IC₅₀) and hemolytic activities (MHC) of peptides against cancer cells and human red blood cells.

<p>^aAnticancer activity (IC₅₀) represents the concentration of peptides at which cell viability was inhibited by 50% in comparison with the untreated cells. The MTT assay was repeated in triplicate, and IC₅₀ value was determined by averaging three repeated experiments.</p><p>^bGM of the anticancer activity (IC₅₀) for the four cancer cell lines.</p><p>^cHemolytic activity (MHC) was determined using human red blood cells after incubation with peptides for 1 h. If no hemolytic activity was observed at 500 μM, a value of 1000 μM was used for calculating the therapeutic index.</p><p>^dTherapeutic index = MHC/IC₅₀. Larger values indicate greater anticancer specificity.</p><p>GM, geometric mean; MHC, minimal hemolytic concentration.</p><p>Anticancer (IC₅₀) and hemolytic activities (MHC) of peptides against cancer cells and human red blood cells.